NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $73,413 | -61.3% | 68,610 | -6.4% | 0.00% | – |
Q2 2023 | $189,821 | -25.9% | 73,290 | +16.7% | 0.00% | – |
Q1 2023 | $256,224 | -14.2% | 62,800 | +5.5% | 0.00% | – |
Q4 2022 | $298,690 | -40.9% | 59,500 | +54.1% | 0.00% | – |
Q3 2022 | $505,000 | +2.0% | 38,600 | 0.0% | 0.00% | – |
Q2 2022 | $495,000 | +17.3% | 38,600 | +39.4% | 0.00% | – |
Q1 2022 | $422,000 | -19.5% | 27,700 | -6.4% | 0.00% | – |
Q4 2021 | $524,000 | -65.2% | 29,600 | -58.6% | 0.00% | -100.0% |
Q3 2021 | $1,505,000 | +110.2% | 71,576 | +97.2% | 0.00% | – |
Q2 2021 | $716,000 | -0.3% | 36,300 | +47.0% | 0.00% | – |
Q1 2021 | $718,000 | -20.5% | 24,700 | -17.1% | 0.00% | – |
Q4 2020 | $903,000 | +82.1% | 29,800 | -4.5% | 0.00% | – |
Q3 2020 | $496,000 | -22.7% | 31,200 | -4.0% | 0.00% | – |
Q2 2020 | $642,000 | +95.1% | 32,500 | +21.7% | 0.00% | – |
Q1 2020 | $329,000 | +21.0% | 26,700 | +81.6% | 0.00% | – |
Q4 2019 | $272,000 | +50.3% | 14,700 | +12.2% | 0.00% | – |
Q3 2019 | $181,000 | – | 13,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
BVF INC/IL | 955,000 | $18,833,000 | 0.71% |